Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 6-arm NCT07126288

Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

A Phase II/III, Seamless, Multicenter, Randomized, Open-Label, Positive-Comparator Controlled Clinical Trial to Evaluate the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.

Conditions Growth Hormone Growth Hormone Deficiency (GHD) Growth Hormone Deficiency in Children

Interventions GB08 Norditropin NordiFlex

Updated 1 time since 2025 Last updated: Aug 17, 2025 Started: Aug 31, 2025 Primary completion: Sep 15, 2028 Completion: Dec 23, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Growth Hormone and Growth Hormone Deficiency (GHD), this trial is actively recruiting participants. The trial is conducted by Shenzhen Kexing Pharmaceutical Co., Ltd. and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2/PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Kexing Pharmaceutical Co., Ltd.

Data source: Kexing Biopharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changchun, China , Chengdu, China , Hangzhou, China , Linyi, China , Meishan, China , Nanchang, China , Nanyang, China , Ningbo, China , Pingxiang, China , Suzhou, China and 4 more locations